Conclusion
In this study, we have demonstrated that testing forBRAFV600E can dictate the optimal strategy for patients without preset preference. These patients pose the greatest challenge to physicians in the decision-making prosses, hence additional evidence-based tools possess great added value. In light of our finding, performing a real-life study, with its costs and risks, is now better justified and encouraged.